Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thrombopoietin mimetic
- Development stage
- Unknown
- Lead developer
- Shandong Spring Pharmaceutical
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Injectable thrombopoietin (TPO) mimetic (specifically QG01) is a recombinant fusion protein being developed by Shandong Quangang Pharmaceutical for the treatment of primary immune thrombocytopenia (ITP). As a TPO receptor agonist, it mimics the action of endogenous thrombopoietin by binding to and activating the TPO receptor (MPL) on the surface of megakaryocytes and their precursors. This activation triggers intracellular signaling pathways that promote the proliferation and differentiation of megakaryocytes, ultimately increasing platelet production. The drug is currently in Phase Ib/II clinical development in China, targeting adult patients with persistent or chronic primary ITP who have not responded adequately to previous treatments.
- Other names
- 注射用TPO模拟物Injectable TPO Mimeticthrombopoietin receptor agonist
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on thrombopoietin mimetic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thrombopoietin mimetic.